Intravenous Prostacyclin in Acute Nonhemorrhagic Stroke


Phase 2 Results

Trial Description

To assess the therapeutic efficacy of prostacyclin in nonhemorrhagic cerebral infarction.


  • Prostacyclin (Epoprostenol)Drug
    Intervention Desc: Prostaglandin, presumed vasodilator.

Trial Design

Randomized, placebo-controlled, double-blind trial involving 80 patients at 5 centers.

Patient Involvement

Patients in the prostacyclin group received a continuous IV infusion of prostacyclin or placebo at an average rate of 8.5 ng/kg/min for 72 hours.


Type Measure Time Frame Safety Issue
Primary Hemodynamic changes, neurologic deficit scores as determined on admission, at Day 3, and at Weeks 1, 2, and 4.